Acetazolamide and Thyroid-Associated Ophthalmopathy; a Preliminary Tested Hypothesis in a TertiaryReferral Center
Medical hypothesis discovery and innovation in ophthalmology,
Vol. 2 No. 4 (2013),
1 December 2013
,
Page 109-112
Abstract
This study evaluated the effect of acetazolamide on thyroid-associated ophthalmopathy (TAO). Patients with a VISA classification index equal to or more than four were enrolled in the study and were randomly assigned into two groups. In both groups, treatment was initiated using prednisolone. Patients in the case group received acetazolamide tablets 250 mg daily in addition to prednisolone. Three months later, the VISA inflammatory score of patients in both groups were determined. Subsequent to intervention with acetazolamide, the VISA inflammatory score of patients in the case group were reduced as follows; orbital pain (57.1% versus 41.7%, P=0.736), eyelid edema (42.8% versus 27.1%, P=0.67), chemosis (53.3% versus 33%, P=0.31), injection of the eyelids (60% versus 41.6%, P=0.342), and conjunctival injection (50% versus 46.13%, P=0.73). However, these reductions were not statistically significant when compared with those observed in the control group (P=0.246). In conclusion, the effect of acetazolamide on all the parameters of the VISA inflammatory score was examined independently. All patients in the case group revealed a reduction in VISA inflammatory score following intervention. However, these reductions were not statistically significant. Further studies with large sample sizes are required.
References
Liesgang TJ, Skuta GL, Cantor LB. Basic and clinical science course. Orbital eyelid and lacrimal system. American Academy of Ophthalmology. 2009-2010;7;46-51.
Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ Ophthalmology. Thyroid 2002:12(10);855-60.
Char DH. Thyroid eye Disease. 3rd ed. Br J Ophthalmol. 1996 October;80(10):922-6. PMCID: PMC505652
Bahn RS. Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-associated ophthalmopathy. Thyroid. 2002 Mar;12(3):193-5. PMID:11952038
Smith TJ. Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid. 2002 Mar;12(3):197-203. PMID:11952039
Dolman PJ, Rootman J. VISA Classification for Gravesorbitopathy. OphthalPlastReconstr Surg. 2006 Sep-Oct;22(5):319-24. Review. PMID: 16985411.
Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol. 1989 Aug;73(8):639-44. PMID: 2765444
Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in management of patient with Graves’ ophthalmopathy. ClinEndocrinol (Oxf). 1997 Jul;47(1):9-14. PMID: 9302365
Katzung B, Masters S, Trevor A. Basic and clinical pharmacology. 12th ed. Toronto: Lange Medical Books, McGraw Hill; 2001. p. 305-309.
Shulkin D, Olson BR, Levey GS. Thyrotoxic periodic paralysis in aLatin-American taking acetazolamide. Am J Med Sci. 1989 May;297(5):337-8. PMID: 2719059.
Nilachandra L, Singh A J, Akoijam B, SinghNB. Hypokalemic Thyrotoxic Periodic Paralysis in Female-A Report of 2 Cases with Review.IJPMR. 2004 April: 48-51.
- Abstract Viewed: 3223 times
- FULL TEXT PDF Downloaded: 3531 times
